Suppr超能文献

阿片受体的新型配体:5'-芳基和5'-杂芳基17-环丙基甲基-4,5α-环氧吡啶并[2',3':6,7]吗啡喃的合成及其构效关系

Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.

作者信息

Ananthan Subramaniam, Khare Naveen K, Saini Surendra K, Davis Peg, Dersch Christina M, Porreca Frank, Rothman Richard B

机构信息

Organic Chemistry Department, Southern Research Institute, Birmingham, AL 35255, USA.

出版信息

Bioorg Med Chem. 2003 Sep 1;11(18):4143-54. doi: 10.1016/s0968-0896(03)00432-2.

Abstract

A series of pyridomorphinans possessing an aryl (10a-s) or heteroaryl (11a-h) substituent at the 5'-position of the pyridine ring of 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinan was synthesized and evaluated for binding and functional activity at the opioid delta, mu, and kappa receptors. All of these pyridomorphinans bound with higher affinity at the delta site than at mu or kappa sites. The binding data on isomeric compounds revealed that there exists greater bulk tolerance for substituents placed at the o-position of the phenyl ring than at m- or p-positions. Among the ligands examined, the 2-chlorophenyl (10l), 2-nitrophenyl (10n), 2-pyridyl (11a), and 4-quinolinyl (11g) compounds bound to the delta receptor with subnanomolar affinity. Compound 10c with the p-tolyl substituent displayed the highest mu/delta selectivity (ratio=42) whereas compound 10l with the 2-chlorophenyl substituent displayed the highest kappa/delta selectivity (ratio=23). At 10 microM concentration, the in vitro functional activity determined using [(35)S]GTP-gamma-S binding assays showed that all of the compounds were antagonists devoid of any significant agonist activity at the delta, mu, and kappa receptors. Antagonist potency determinations of three selected ligands revealed that the p-tolyl compound 10c is a potent delta selective antagonist. In the [(35)S]GTP-gamma-S assays this compound had a functional antagonist K(i) value of 0.2, 4.52, and 7.62 nM at the delta, mu, and kappa receptors, respectively. In the smooth muscle assays 10c displayed delta antagonist potency with a K(e) value of 0.88 nM. As an antagonist, it was 70-fold more potent at the delta receptors in the MVD than at the mu receptors in the GPI. The in vitro delta antagonist profile of this pyridomorphinan 10c resembles that of the widely used delta selective antagonist ligand naltrindole.

摘要

合成了一系列在17-环丙基甲基-4,5α-环氧吡啶并[2',3':6,7]吗啡喃吡啶环的5'-位带有芳基(10a-s)或杂芳基(11a-h)取代基的吡啶吗啡喃,并对其在阿片δ、μ和κ受体上的结合及功能活性进行了评估。所有这些吡啶吗啡喃在δ位点的结合亲和力高于μ或κ位点。对异构体化合物的结合数据表明,与苯环间位或对位的取代基相比,邻位取代基具有更大的体积耐受性。在所研究的配体中,2-氯苯基(10l)、2-硝基苯基(10n)、2-吡啶基(11a)和4-喹啉基(11g)化合物与δ受体的结合亲和力低于纳摩尔。具有对甲苯基取代基的化合物10c表现出最高的μ/δ选择性(比率 = 42),而具有2-氯苯基取代基的化合物10l表现出最高的κ/δ选择性(比率 = 23)。在10 μM浓度下,使用[(35)S]GTP-γ-S结合试验测定的体外功能活性表明,所有化合物在δ、μ和κ受体上均为拮抗剂,无任何显著的激动剂活性。对三种选定配体的拮抗剂效价测定表明,对甲苯基化合物10c是一种有效的δ选择性拮抗剂。在[(35)S]GTP-γ-S试验中,该化合物在δ、μ和κ受体上的功能性拮抗剂K(i)值分别为0.2、4.52和7.62 nM。在平滑肌试验中,10c表现出δ拮抗剂效价,K(e)值为0.88 nM。作为拮抗剂,它在MVD中的δ受体上的效力比在GPI中的μ受体上高70倍。这种吡啶吗啡喃10c的体外δ拮抗剂特征与广泛使用的δ选择性拮抗剂配体纳曲吲哚相似。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验